3 Ways To Address Sterility Assurance Requirements Of The EU GMP Annex 1
Source: Chargepoint Technology
By Ben Wylie
Manufacturers are now in need of action with the August 2023 release of the latest issue of the EU GMP Annex 1 for the manufacture of sterile medicinal products. There are a number of considerations to the way drug developers and their CDMO partners handle their products and solutions to ensure sterility assurance.
Learn about the three key proactive steps companies need to take to meet the Annex 1 sterility assurance requirements.
access the White Paper!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
Chargepoint Technology
This website uses cookies to ensure you get the best experience on our website. Learn more